(Credit-Canva)
The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.
Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.
Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.
Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.
Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.
Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.
Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.
According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.
All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.
Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.
Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.
Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.
People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.
Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.
Credit: AI-generated image
The Indian Society of Anaesthesiologists (ISA) has issued an urgent advisory asking anaesthesiologists and hospitals across the country to immediately stop administering Hyperbaric Bupivacaine manufactured by Themis for spinal anaesthesia until further notice.
Themis Hyperbaric Bupivacaine is commonly administered as a spinal anaesthesia. According to the ISA and the Anaesthesia Patient Safety Association (APSA), the anaesthesia resulted in several suspected adverse events.
These reports were significant enough to warrant an immediate nationwide safety alert, even though the exact cause and frequency of the adverse events have not been revealed yet.
However, according to Medical Dialogues, the Indian Society of Anaesthesiologists has suspected that the adverse incidents linked to Themis Hyperbaric Bupivacaine were reported at Apollo Hospitals and Yashoda Hospitals. They also said that Adverse Drug Reactions (ADRs) related to the drug have been reported, and an investigation is underway.
The associations also stressed that the advisory is strictly precautionary and does not imply that the drug is defective or that Themis is responsible for any negligence or unethical practices.
Apart from stopping the administration of Themis Hyperbaric Bupivacaine, the advisory has also asked hospitals and healthcare facilities to:
Dr Sherry Mathews, President of the Hyderabad Metro City Branch of the Indian Society of Anaesthesiologists, said, “This is a precautionary advisory issued in the interest of patient safety. Reports of serious adverse events have been received from multiple hospitals, and until the investigation is completed, we have advised doctors to stop using the product.”
Also read: Are Sea Squirts The Future Of Skin Cancer Treatment? New Study Says They Can Kill Melanoma Cells
A separate notice issued by the ISA's Hyderabad Metro City Branch directed consultants, resident doctors, anaesthesia technicians and operation theatre staff to immediately stop the use of Themis Bupivacaine for spinal anaesthesia.
It also said that no ampoules of the product should be used for neuraxial administration until an official clearance is issued. It added that any inadvertent use must be reported to the head of the department without fail.
The authorities are currently investigating these suspected adverse reactions, particularly their nature and association with the drug.
Themis Hyperbaric Bupivacaine, marketed under brand names like Bupicain Heavy, is manufactured by Themis Medicare Limited, a 53-year-old Indian pharmaceutical company.
It contains Bupivacaine hydrochloride 0.5% (5 mg/mL), a local anaesthetic. It also contains Dextrose, which makes the solution hyperbaric (heavier than cerebrospinal fluid), which helps anaesthesiologists control how the anaesthetic spreads through the spinal canal.
Hyperbaric bupivacaine is commonly used for:
Hyperbaric bupivacaine is widely trusted for spinal anaesthesia globally. Many pharmaceutical companies manufacture it. The concern raised by the Indian Society of Anaesthesiologists is not against the drug, but about one manufacturer's production.
Credit: Times Network
The Times Network India Health Summit 2026 – South Edition, held on June 20 in Hyderabad, honored the outstanding contributions of doctors and innovations across the Indian healthcare sector.
The event brought together leading voices from government, medicine, research, and the healthcare industry to discuss the future of India's healthcare system.
Across three panel discussions, experts deliberated on the growing burden of obesity and anemia in the country, the role of artificial intelligence in healthcare and whether AI could outpace doctors, as well as the increasing incidence of violence against doctors and healthcare workers.
The summit featured renowned doctors, policymakers, hospital leaders, researchers and healthcare innovators. Discussions also covered preventive healthcare, artificial intelligence, women's health, public health policy and medical innovation.
The event was powered by Tamashii, with Gigglu as the associate partner, BMW Krishna Automotive as the automobile partner, Sumadhura as the real estate partner, and VOH (Voice of Healthcare) as the knowledge partner.
| S.No | Award Category | Award Winner Name |
| 1 | Eminent Excellence in Functional Neuro Surgery (Telangana) | Dr Dhanunjaya Rao - Apollo Hospitals |
| 2 | Eminent Excellence in Robotic Joint Replacement Surgery (Telangana) | Dr Vikram Byre - Yashoda Hospitals |
| 3 | Legendary Excellence in Joint Replacement Surgeries (Telangana) | Dr K Sudhir Reddy - Landmark Hospitals |
| 4 | Legendary Excellence in Internal Medicine & Intensive Care (Telangana) | Dr Rajib Paul - Apollo Hospitals |
| 5 | Centre of Excellence in Varicose Veins | AVIS Vascular Center |
| 6 | Legendary Excellence in Neurosurgery & Brain Stroke Prevention Public Health Services (Telangana) | Dr Uday Goutam - Goutam Neuro Care |
| 7 | Outstanding Philanthropic Contribution to Hearing Impairment Rehabilitation & Inclusion | SAHI (Society to Aid the Hearing Impaired) |
| 8 | Centre of Excellence in Advanced Fertility Treatments (Telangana) | Hegde Fertility |
| 9 | Lifetime Achievement Award in Gastrointestinal & Minimally Invasive Surgery (Telangana) | Dr G V Rao - Director AIG Hospitals |
| 10 | Best Emerging Multi Specialty Hospital (Telangana) | Sindhu Hospitals |
| 11 | Centre of Excellence in Advanced Dentistry (Khammam) | Sri Srinivasam Dental Hospital (Khammam) |
| 12 | Centre of Excellence in Advanced Personalized Orthopedic Care (Telangana) | My Ortho Centre |
| 13 | Legendary Excellence in Dental Implants (Telangana) | Dr Venkat Ratna Nag - The Dental Specialists |
| 14 | Legendary Excellence in Advanced Otology (Telangana) | Dr Jaswinder Singh Saluja - Apollo Hospitals |
| 15 | Excellence in Robotic & Minimally Invasive Gynecological Surgery (Telangana) | Dr T Rajeshwari Reddy – Continental Hospitals |
| 16 | Eminent Excellence in Transplant Pulmonology (Telangana) | Dr Tapaswi Krishna - Yashoda Hospitals |
| 17 | Legendary Excellence in Precision Eye Surgery (Telangana) | Dr Sangeeta Das - Malla Reddy Hospital |
| 18 | Excellence in Agentic AI for Clinical Diagnostics | Neurologic.AI |
| 19 | Centre of Excellence in Advanced Clear Aligner & Smile Design Treatments (Telangana) | PARK Dental Care |
| 20 | Eminent Excellence in Surgical Oncology & Robotic Surgery (Telangana) | Dr Ajay Chanakya Vallabhaneni |
| 21 | Lifetime Achievement in Women's Healthcare & Maternal Excellence | Dr Evita Fernandez - Fernandez Hospitals |
| 22 | Best Emerging Hospital in Vascular & Plastic Surgery (Telangana) | IKIGAI Hospitals |
| 23 | Emerging Excellence in Voice & Airway Disorders Management (Telangana) | Dr Madhav Koka - Apollo Hospitals |
| 24 | Legendary Excellence in Advanced Proctology & Anal Canal Surgery (Telangana) | Dr Sanjeev Singh Yadav - EPIC International Hospital |
| 25 | Lifetime Achievement Award in Global Oncology Excellence | Dr Nori Dattatreyudu |
| 26 | Excellence in Advanced Medical Care & Innovation | AJ Hospital & Research Centre |
| 27 | Visionary Excellence in Robotic Laparoscopic Surgery | Dr Rooma Sinha - Apollo Hospitals |
Credit: Instagram
Serena Williams has openly spoken up about her weight loss struggle after the birth of her second daughter in 2023. As she returns to competitive tennis at the age of 44, discussion around her much leaner appearance was sparked again. Williams has been candid about attributing her weight loss to a GLP-1 drug called Zepbound.
As Serena Williams made a high-profile return to singles competition at Wimbledon on June 30, fans did not miss the difference in her physique.
In 2025, Williams revealed that she was able to shed about 34 to 38 pounds (15 to 17 kg) with the help of the prescription GLP-1 medication Zepbound (tirzepatide), alongside regular exercise and healthy eating.
Her comeback to the sport also sparked debate over whether GLP-1 medications provide a competitive advantage and if they should be banned. But as of now, GLP-1 drugs are not banned by the anti-doping authorities.
She also emphasized that the medication was an addition to, not a replacement for her existing fitness habits. According to NBC, she announced a partnership with the company Ro, which prescribes GLP-1 medications through telehealth.
Also read: Did Donald Trump Take Eli Lilly's Weight Loss Drug? What Did White House Say
The RO website features Williams, stating: “After kids, she was doing everything right, but nothing worked. Ro finally helped her get back to her strongest self," it says. "After losing weight with another GLP-1 provider, Serena chose Ro to continue her weight loss journey. She has used both branded vials and pens.”
In a conversation with People that her weight struggle began after the birth of her daughter. She said that she was not able to get to the weight she wanted regardless of her efforts.
She said, “It was crazy because I'd never been in a place like that in my life where I worked so hard, ate so healthy, and could never get down to where I needed to be at.”
Apart from weight loss, she also spoke about other benefits she experienced after starting Zepbound.
She said, “I just can do more. I'm more active. My joints don't hurt as much. I just feel like something as simple as just getting down is a lot easier for me. And I do it a lot faster. I feel like I have a lot of energy, and it's great. I just feel pretty good about it.”
Zepbound’s active ingredient is tirzepatide. While it is called GLP-1 medication, it is more than that. It mirrors two hormones that your body naturally releases after you eat:
This hormone makes you feel full sooner, slows stomach emptying, so food stays in your stomach longer, reducing appetite. It also helps the pancreas release insulin when blood sugar rises.
This improves insulin response, enhances metabolism, and works together with GLP-1 to produce greater weight loss than GLP-1 alone.
Zepbound's two-way action is the biggest factor that distinguishes it from Ozempic. The latter mimics only one hormone, GLP 1, which reduces appetite and hunger by promoting a feeling of fullness.
Zepbound, on the other hand, performs the function of GLP-1 while also improving insulin sensitivity and fat metabolism effectively.
© 2024 Bennett, Coleman & Company Limited